SCHEMBL3973027

SCHEMBL3973027

CCC(CC)N1CCN(c2ccc(Cc3ccccc3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49
HRH3 Q9Y5N1 3/20 0.47
LMNA P02545 1/20 0.45
CHRNA7 P36544 1/20 0.45
DRD4 P21917 3/20 0.44
OPRM1 P35372 1/20 0.44
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
DRD2 P14416 2/20 0.42
SIGMAR1 Q99720 1/20 0.42
POLB P06746 2/20 0.42
HTR1A P08908 1/20 0.41
SMO Q99835 1/20 0.41
IDO1 P14902 1/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
MC4R P32245 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3973103 0.98 HRH3 (0.48) KDM4EALDH1A1TP53HRH3LMNA
SCHEMBL23315994 0.78 ADRB1 (0.48) KDM4EALDH1A1HRH3MAPTNPSR1
SCHEMBL7582559 0.78 NCF1 (0.57) KDM4EALDH1A1HRH3DRD4MAPT
SCHEMBL3967830 0.78 ALDH1A1 (0.60) KDM4EALDH1A1TP53HRH3LMNA
SCHEMBL1048101 0.77 MAPT (0.61) KDM4EALDH1A1TP53HRH3LMNA
Hydrochloric Acid SCHEMBL3967645 0.77 ALDH1A1 (0.59) KDM4EALDH1A1TP53HRH3LMNA
SCHEMBL5301158 0.76 CHKA (0.58) KDM4EALDH1A1TP53LMNADRD4
SCHEMBL27847240 0.75 NCF1 (0.48) KDM4EALDH1A1LMNADRD4MAPT
SCHEMBL28198974 0.74 CHKA (0.56) KDM4EALDH1A1TP53LMNAMAPT
SCHEMBL26416834 0.74 CHRNA7 (0.47) KDM4EALDH1A1TP53HRH3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101805298-A Novel aryl-with heteroaryl-piperazine HIGH POINT PHARMACEUTICALS LLC 2010-08-18 CN disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
CN-1628109-A Novel aryl-and heteroaryl-piperazines NOVO NORDISK AS (DK) 2005-06-15 CN disclosed
EP-1474401-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2004-11-10 EP disclosed
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC 2003-12-25 US disclosed
WO-2003066604-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HRH3, HRH2, HRH4 KDM4E 1574/4885ALDH1A1 2719/4885TP53 4116/4885
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HRH3, HRH2, HRH4 KDM4E 1574/4885ALDH1A1 2719/4885TP53 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.